Cybin Inc., a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. The company's development pipeline includes CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD), as well as in preclinical trials for alcohol use disorder; CYB004, a deuterated dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders; SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 completed phase 1, 1b, and 1/2a for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat neuroinflammation, as well as has a research pipeline of investigational psychedelic-based compounds. The company has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada. Show more

Location: 100 King Street West, Toronto, ON, M5X 1C9, Canada | Website: https://www.cybin.com | Industry: Biotechnology | Sector: Healthcare


Market Cap

183.9M

52 Wk Range

$4.81 - $13.88

Previous Close

$7.73

Open

$7.84

Volume

428,944

Day Range

$7.67 - $8.00

Enterprise Value

43.02M

Cash

135M

Avg Qtr Burn

-25.33M

Insider Ownership

207.96%

Institutional Own.

42.41%

Qtr Updated

03/31/25


Drug Pipeline

Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.